Shares of Alcobra Ltd. (NASDAQ:ADHD) have been assigned an average recommendation of “Hold” from the eleven brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $2.02.

Several equities research analysts have recently issued reports on ADHD shares. Roth Capital set a $4.00 price objective on shares of Alcobra and gave the company a “buy” rating in a research report on Wednesday, May 31st. ValuEngine cut shares of Alcobra from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of Alcobra from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research report on Friday, June 2nd. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $1.25 price objective on shares of Alcobra in a research report on Monday, June 12th.

Alcobra (NASDAQ:ADHD) opened at 1.02 on Friday. The company’s market cap is $28.11 million. Alcobra has a one year low of $0.83 and a one year high of $5.36. The stock has a 50 day moving average of $1.10 and a 200-day moving average of $1.16.

Alcobra (NASDAQ:ADHD) last released its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. On average, equities analysts predict that Alcobra will post ($0.50) EPS for the current fiscal year.

WARNING: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/18/alcobra-ltd-adhd-given-consensus-recommendation-of-hold-by-analysts.html.

A number of large investors have recently made changes to their positions in ADHD. Worth Venture Partners LLC boosted its stake in shares of Alcobra by 35.6% in the second quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 71,465 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Alcobra by 7,251.0% in the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 101,514 shares in the last quarter. Finally, Royce & Associates LP boosted its stake in shares of Alcobra by 15.5% in the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock valued at $849,000 after buying an additional 100,000 shares in the last quarter. Institutional investors own 38.12% of the company’s stock.

Alcobra Company Profile

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Analyst Recommendations for Alcobra (NASDAQ:ADHD)

Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.